Page 211 - Read Online

Galletti et al. Using CTCs in prostate cancer

K, Kuhn P. High-definition imaging of circulating tumor cells and 33. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing
associated cellular events in non-small cell lung cancer patients: a H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Circulating
longitudinal analysis. Phys Biol 2012;9:016004. tumor cells predict survival benefit from treatment in metastatic
19. Werner SL, Graf RP, Landers M, Valenta DT, Schroeder M, Greene castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
SB, Bales N, Dittamore R, Marrinucci D. Analytical validation and 34. Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, Xiao
capabilities of the epic CTC platform: enrichment-free circulating W, Davis MM, Pease RF, Mindrinos MN, Jeffrey SS, Davis RW.
tumour cell detection and characterization. J Circulating Biomarkers Isolating highly enriched populations of circulating epithelial cells
2015;4:3. and other rare cells from blood using a magnetic sweeper device. Proc
20. Anantharaman A, Friedlander T, Lu D, Krupa R, Premasekharan G, Natl Acad Sci U S A 2009;106:3970-5.
Hough J, Edwards M, Paz R, Lindquist K, Graf R, Jendrisak A, Louw 35. Cann GM, Gulzar ZG, Cooper S, Li R, Luo S, Tat M, Stuart S, Schroth
J, Dugan L, Baird S, Wang Y, Dittamore R, Paris PL. Programmed G, Srinivas S, Ronaghi M, Brooks JD, Talasaz AH. mRNA-Seq of
death-ligand 1 (PD-L1) characterization of circulating tumor cells single prostate cancer circulating tumor cells reveals recapitulation of
(CTCs) in muscle invasive and metastatic bladder cancer patients. gene expression and pathways found in prostate cancer. PLoS One
BMC Cancer 2016;16:744. 2012;7:e49144.
21. Harouaka RA, Nisic M, Zheng SY. Circulating tumor cell enrichment 36. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff
based on physical properties. J Lab Autom 2013;18:455-68. SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson
22. Desitter I, Guerrouahen BS, Benali-Furet N, Wechsler J, Janne PA, MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner
Kuang Y, Yanagita M, Wang L, Berkowitz JA, Distel RJ, Cayre YE. M, Haber DA, Maheswaran S. Circulating breast tumor cells exhibit
A new device for rapid isolation by size and characterization of rare dynamic changes in epithelial and mesenchymal composition. Science
circulating tumor cells. Anticancer Res 2011;31:427-41. 2013;339:580-4.
23. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, Capron 37. Capoun O, Mikulova V, Jancikova M, Honova H, Kolostova K,
F, Franco D, Pazzagli M, Vekemans M, Lacour B, Brechot C, Sobotka R, Michael P, Zima T, Hanus T, Soukup V. Prognosis of
Paterlini-Brechot P. Isolation by size of epithelial tumor cells: a new castration-resistant prostate cancer patients - use of the AdnaTest®
method for the immunomorphological and molecular characterization system for detection of circulating tumor cells. Anticancer Res
of circulatingtumor cells. Am J Pathol 2000;156:57-63. 2016;36:2019-26.
24. Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, 38. Todenhofer T, Hennenlotter J, Feyerabend S, Aufderklamm S,
Laplanche A, Chauchereau A, Lacroix L, Planchard D, Le Moulec Mischinger J, Kuhs U, Gerber V, Fetisch J, Schilling D, Hauch S,
S, Andre F, Fizazi K, Soria JC, Vielh P. A direct comparison of Stenzl A, Schwentner C. Preliminary experience on the use of the
CellSearch and ISET for circulating tumour-cell detection in patients AdnaTest® system for detection of circulating tumor cells in prostate
with metastatic carcinomas. Br J Cancer 2011;105:847-53. cancer patients. Anticancer Res 2012;32:3507-13.
25. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive 39. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G,
C. Molecular analysis of circulating tumour cells-biology and Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M.
biomarkers. Nat Rev Clin Oncol 2014;11:129-44. Her-2-neu expression and progression toward androgen independence
26. Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, Clack G, in human prostate cancer. J Natl Cancer Inst 2000;92:1918-25.
Ranson M, Blackhall F, Dive C. Circulating tumor cells as a window 40. Scher HI. HER2 in prostate cancer -- a viable target or innocent
on metastasis biology in lung cancer. Am J Pathol 2011;178:989-96. bystander? J Natl Cancer Inst 2000;92:1866-8.
27. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, 41. Hanssen A, Wagner J, Gorges TM, Taenzer A, Uzunoglu FG, Driemel
Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur C, Stoecklein NH, Knoefel WT, Angenendt S, Hauch S, Atanackovic
R, Stott SL, Shioda T, Ramaswamy S, Ting DT, Lin CP, Toner M, Haber D, Loges S, Riethdorf S, Pantel K, Wikman H. Characterization of
DA, Maheswaran S. Circulating tumor cell clusters are oligoclonal different CTC subpopulations in non-small cell lung cancer. Sci Rep
precursors of breast cancer metastasis. Cell 2014;158:1110-22. 2016;6:28010.
28. Lazar DC, Cho EH, Luttgen MS, Metzner TJ, Uson ML, Torrey M, 42. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC,
Gross ME, Kuhn P. Cytometric comparisons between circulating Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De
tumor cells from prostate cancer patients and the prostate-tumor- Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade
derived LNCaP cell line. Phys Biol 2012;9:016002. SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance
29. Meunier A, Hernandez-Castro JA, Turner K, Li K, Veres T, Juncker to enzalutamide and abiraterone in prostate cancer. N Engl J Med
D. Combination of mechanical and molecular filtration for enhanced 2014;371:1028-38.
enrichment of circulating tumor cells. Anal Chem 2016;88:8510-7. 43. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L,
30. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis
C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in UJ, Tompkins RG, Haber DA, Toner M. Isolation of rare circulating
the peripheral blood of all major carcinomas but not in healthy tumour cells in cancer patients by microchip technology. Nature
subjects or patients with nonmalignant diseases. Clin Cancer Res 2007;450:1235-9.
2004;10:6897-904. 44. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA,
31. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Jr.,
MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S,
Circulating tumor cells, disease progression, and survival in metastatic Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner
breast cancer. N Engl J Med 2004;351:781-91. M. Isolation of circulating tumor cells using a microvortex-generating
32. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail herringbone-chip. Proc Natl Acad Sci U S A 2010;107:18392-7.
NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing 45. Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST,
H, Terstappen LW, Meropol NJ. Relationship of circulating tumor Nanus DM, Giannakakou PA, Kirby BJ. Capture of circulating tumor
cells to tumor response, progression-free survival, and overall cells from whole blood of prostate cancer patients using geometrically
survival in patients with metastatic colorectal cancer. J Clin Oncol enhanced differential immunocapture (GEDI) and a prostate-specific
2008;26:3213-21. antibody. Lab Chip 2010;10:27-9.
Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ September 27, 2017 203